China Everbright Limited Announces 2021 Interim Results
HONG KONG, Aug. 26, 2021 /PRNewswire/ -- Financial Highlights (in HK$ hundred million) 2021 1H 2020 1H Change Total amount of income 31.33 20.13 +56% Profit attributable to shareholders of the Company 17.81 7.65 +133% - Profit from direct business operations (including profit from ...
China Everbright Limited Announces 2020 Annual Results
HONG KONG, March 19, 2021 /PRNewswire/ -- Financial Highlights of 2020 Annual Results * Significant fundraising growth counters trend. Scale of newly-raised funds under CEL was approximatelyHK$27.15 billion, with the total AUM reaching HK$182.8 billion, a year-on-year increase of 16%, reachin...
China Everbright Limited Core Business Records Stable and Healthy Performance in 2018
Total AUM Increases 11% to HK$143.5 billion HONG KONG, March 28, 2019 /PRNewswire/ -- (HK$ 100 million) 2018 2017 Change 2018 (excluding the impact of HKFRS 9) Change Total AUM 1,435 1,291 +11% -- -- Total Income 46.96 55.29 (15%) 58.68 +6% Profit attributable to shareholder...
2018 Everbright Investment Conference Successfully Held in Hangzhou
Over 900 Global Industry Leaders Join to Capture More Cross-border Investment Opportunities Arise from Market Challenges HANGZHOU, China, Oct. 24, 2018 /PRNewswire/ -- China Everbright Limited ("Everbright", stock code: 165.HK), the flagship overseas investment platform of China Everbright Group...
Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech to Jointly Acquire U.S. Innovative Biotechnology Company Ambrx
SHANGHAI, May 22, 2015 /PRNewswire/ -- A consortium ("the Consortium") consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited's healthcare fund ("CEL Healthcare Fund"), and WuXi PharmaTech announced today that the Consortium has sign...
